Latest From OrthoSera GmbH
Start-ups raised $2.41 billion in Q4 2015. Biopharma companies penned 29 alliances; seven acquisitions were signed in the biopharma and diagnostics industries.
Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced November-December 2015.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced November through December 2015.
- Gene Therapy, Cell Therapy
- Therapeutic Areas
- Dental & Oral Products
- Musculoskeletal & Connective Tissue Disorders
- Lacerta Technologies
- Western Europe
- Parent & Subsidiaries
- OrthoSera GmbH
- Senior Management
Zsombor Lacza, MD, PhD, CEO
Björn Ehring, CFO
- Contact Info
Phone: 664 883 16206
Krems an der Donau, 3500
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.